Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas

Malignant progression of astrocytoma is a multistep process with the integration of genetic abnormalities including grade progression and subtypes transition. Established biomarkers of astrocytomas, like IDH1 and TP53 mutation, were not associated with malignant progression. To identify new biomarker(s) contributing to malignant progression, we collected 252 samples with whole genome mRNA expression profile [34 normal brain tissue (NBT), 136 grade II astrocytoma (AII) and 82 grade III astrocytoma (AIII)]. Bioinformatics analysis revealed that EMT-associated pathways were most significantly altered along with tumor grades progress with up-regulation of 17 genes. Up-regulation of these genes was further confirmed by RNA-sequencing in 128 samples. Survival analysis revealed that high expression of these genes indicates a poor survival outcome. We focused on TGFB1I1 (TGF-β1 induced transcript 1) whose expression correlation with WHO grades was further validated by qPCR in 6 cell lines of different grades and 49 independent samples (36 AIIs and 13 AIIIs). High expression of TGFB1I1 was found associated with subtype transition and EMT pathways activation. The conclusion was confirmed using immunohistochemistry in tissue microarrays. Studies in vitro and in vivo using TGF-β1 and TGFB1I1 shRNA demonstrated that TGFB1I1 is required for TGF-β stimulated EMT that contributes to malignant progression of astrocytomas.

[1]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[2]  Guoqing Hu,et al.  Transforming Growth Factor-β1-induced Transcript 1 Protein, a Novel Marker for Smooth Muscle Contractile Phenotype, Is Regulated by Serum Response Factor/Myocardin Protein* , 2011, The Journal of Biological Chemistry.

[3]  K. Nose,et al.  Hic-5 communicates between focal adhesions and the nucleus through oxidant-sensitive nuclear export signal. , 2003, Molecular biology of the cell.

[4]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[5]  C. Turner,et al.  Hic‐5 contributes to epithelial‐mesenchymal transformation through a RhoA/ROCK‐dependent pathway , 2007, Journal of cellular physiology.

[6]  H. Shirato,et al.  Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. , 2014, Neuro-oncology.

[7]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[8]  K. Ichimura,et al.  Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. , 2000, Cancer research.

[9]  Andrew E. Sloan,et al.  Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma , 2014, PloS one.

[10]  D. Garbossa,et al.  Molecular biology of gliomas: present and future challenges , 2014, Translational medicine @ UniSa.

[11]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[12]  C. Turner,et al.  Hic-5 promotes invadopodia formation and invasion during TGF-β–induced epithelial–mesenchymal transition , 2012, The Journal of cell biology.

[13]  Yue Xiong,et al.  p15PAF, a novel PCNA associated factor with increased expression in tumor tissues , 2001, Oncogene.

[14]  N. Tandon,et al.  ZIP4 is a novel molecular marker for glioma. , 2013, Neuro-oncology.

[15]  Yusuke Nakamura,et al.  Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. , 2007, Cancer research.

[16]  C. Turner,et al.  Hic-5 promotes invadopodia formation and invasion during TGF-b–induced epithelial–mesenchymal transition , 2012 .

[17]  Lei Han,et al.  Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. , 2012, Neuro-oncology.

[18]  Travis J Cohoon,et al.  Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. , 2013, Cancer discovery.

[19]  Se Hoon Kim,et al.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. , 2013, Cancer cell.

[20]  G. Fuller,et al.  Insulin-like growth factor binding protein 2 promotes glioma development and progression , 2007, Proceedings of the National Academy of Sciences.

[21]  P. Kleihues,et al.  The Definition of Primary and Secondary Glioblastoma , 2012, Clinical Cancer Research.

[22]  Lei Han,et al.  AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. , 2013, Cancer research.

[23]  Jianguo Song.  EMT or apoptosis: a decision for TGF-beta. , 2007, Cell research.

[24]  Y. Mao,et al.  Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival , 2013, PloS one.

[25]  R. McLendon,et al.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.

[26]  L. Mariani,et al.  Alterations in the RB1 Pathway in Low‐grade Diffuse Gliomas Lacking Common Genetic Alterations , 2011, Brain pathology.

[27]  Y. Nakazato.  [The 4th Edition of WHO Classification of Tumours of the Central Nervous System published in 2007]. , 2008, No shinkei geka. Neurological surgery.

[28]  Wei Yan,et al.  MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. , 2012, Oncology reports.